News | Implantable Cardiac Monitor (ICM) | July 11, 2024

Amvia Sky Launched in Canada, the World’s First Pacemaker Approved for LBBAP

First implant of Amvia Sky in Canada performed at the Centre Hospitalier de l'Université de Montréal

First implant of Amvia Sky in Canada performed at the Centre Hospitalier de l'Université de Montréal

July 11, 2024 — Dr. Fadi Mansour performed the first Canadian implant of BIOTRONIK’s newest pacemaker and CRT-P generation earlier this year at the Centre Hospitalier de l'Université de Montréal. The patient received an Amvia Sky HF-T QP triple chamber pacemaker device. The first implant follows the full market release of BIOTRONIK’s newest family of pacemaker and CRT-P devices, featuring patient-centric technologies for better patient care and simplified workflows.

“The Amvia Sky HF-T QP offers a significant number of advanced features, making it the most complete CRT-P on the market including streamlined care pathways,” commented Dr. Mansour after the procedure.

The Amvia Sky system offers the following new features:

  • Industry-leading choice with 20 left ventricular (LV) pacing polarities, automatically tested in less than 2.5 minutes.
  • CRT AutoAdapt which automatically adjusts to changes in the patient’s condition for a more personalized response.
  • Enhanced Closed Loop Stimulation (CLS) rate adaptation technology.
  • Atrial arrhythmia management tools, including atrial antitachycardia pacing (ATP).
  • Streamlined Care Pathways.
  • Next-generation MRI access with MRI Guard 24/7.

“BIOTRONIK is dedicated to continually improving our technologies, and the Amvia Sky family is a great example of this commitment,” said Angela McGonigle, Country Director BIOTRONIK Canada. “Our latest family of pacemaker and CRT-P devices offers advanced features for optimized therapy and improved workflow simplification for Allied Health Professionals.”

For more information: www.biotronik.com


Additional Content

News | Heart Failure

Oct. 14, 2026 — GLP-1 weight loss drugs known may help protect against heart failure even at doses too low to produce ...

Home October 19, 2026
Home
Feature | Heart Failure | Kyle Hardner

The shift toward steering appropriate cardiovascular cases to outpatient settings is gaining momentum, driven by a ...

Home September 11, 2026
Home
News | Heart Failure

Sept. 9, 2026— Atman Health has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to develop an ...

Home September 11, 2026
Home
News | Heart Failure

Aug. 31, 2026 — A new heart failure (HF) treatment effect calculator could help overcome one of the largest barriers to ...

Home August 31, 2026
Home
News | Heart Failure

July 28, 2026 — Abbott has initiated the Treat TR study, a post-market study of the company’s TriClip transcatheter edge ...

Home July 29, 2026
Home
Subscribe Now